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Abstract
Introduction—Many therapeutics are limited to parenteral administration. Oral administration is 
a desirable alternative because of the convenience and increased compliance by patients, especially 
for chronic diseases that require frequent administration. Polymeric nanoparticles are one 
technology being developed to enable clinically feasible oral delivery.
Areas covered—This review discusses the challenges associated with oral delivery. Strategies 
used to overcome gastrointestinal barriers using polymeric nanoparticles will be considered, 
including mucoadhesive biomaterials and targeting of nanoparticles to transcytosis pathways 
associated with M cells and enterocytes. Applications of oral delivery technologies will also be 
discussed, such as oral chemotherapies, oral insulin, treatment of inflammatory bowel disease, and 
mucosal vaccinations.
Expert opinion—There have been many approaches used to overcome the transport barriers 
presented by the gastrointestinal tract, but most have been limited by low bioavailability. Recent 
strategies targeting nanoparticles to transcytosis pathways present in the intestines have 
demonstrated that it is feasible to efficiently transport both therapeutics and nanoparticles across 
the intestines and into systemic circulation after oral administration. Further understanding of the 
physiology and pathophysiology of the intestines could lead to additional improvements in oral 
polymeric nanoparticle technologies and enable the translation of these technologies to clinical 
practice.
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1. Introduction
1.1 Motivation for Oral Delivery
Over the past 50 years, there has been an explosion in biomedical research that has led to a 
remarkable understanding of the pathophysiology associated with many diseases. Armed 
with this knowledge, many new therapies are being developed that could have a significant 
impact on disease treatment and patient outcomes. Many of these new therapies fall into a 
pharmaceutical class known as biologics, which include peptide hormones, antibodies, 
growth factors, enzymes, vaccines, and nucleic acids. In fact, more than 100 biologics have 
been developed over the past 30 years to treat diseases ranging from cancer and diabetes to 
rare genetic disorders, generating $64 billion in the US market in 2012 [1]. Furthermore, 
combining biological understanding with engineering and materials science principles has 
led to the development of nanoparticle (NP)-based therapeutics, or nanomedicines. This 
emerging class of therapeutics is now entering clinical trials [2–4], and could have a 
significant impact of the treatment of many diseases [5,6].
Many diseases that would benefit from biologics or nanomedicines are chronic, requiring 
frequent treatments over prolonged periods of time. Unfortunately, these therapeutics are 
currently restricted to parenteral administration methods, which could limit their use. 
Injection-based therapies can suffer from poor patient compliance and reduced efficacy due 
to the pain and inconvenience associated with treatment regimens. Therefore, alternate 
routes of administration, such as transdermal, nasal, buccal, pulmonary, and oral, are under 
investigation as a means to improve these therapies. Of these alternate routes, oral is 
considered the most desirable, especially for chronic diseases, because of the convenience 
and improved compliance [7–11]. In clinical studies, oral administration of chemotherapy is 
not only more convenient for patients, it has also been shown in some cases to have less 
drug-related adverse effects due to favorable pharmacokinetics [12]. In addition, oral 
formulations have advantages for physicians such as flexible dosing schedules, less demands 
on staff, and reduced costs through less hospital or clinic visits [13–17].
1.2 Physiology of the Gastrointestinal Tract
Oral delivery technologies can be used to treat diseases of the gastrointestinal (GI) tract 
locally or to enable therapeutics to reach systemic circulation. For therapeutics to reach the 
bloodstream after oral administration, they must pass through the gastrointestinal (GI) tract 
and be absorbed. The small intestine plays the primary role in regulating the absorption of 
material (Figure 1). It has several features specific for this role, with macroscopic folds on 
the inner surface and microscopic finger-like projections called villi that significantly 
increase the absorption surface area [18]. The villi epithelium is a polarized cell monolayer 
that acts as a barrier to tightly regulate the transport of material from the external 
environment (intestinal lumen) to the lamina propria [19]. The epithelial cells rest on top of 
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an extracellular matrix called the basal lamina that divides the epithelium from the lamina 
propria. The lamina propria within each villus contains a network of capillaries for 
absorption of molecules transported across the epithelial barrier and a blunt-ended lymphatic 
vessel called a lacteal for absorption of larger particles such as fats. The capillaries converge 
into venules and, eventually, the portal vein that transports material to the liver. The 
lymphatic vessels carry material through the lymph nodes before entering into the 
bloodstream through the thoracic duct.
The intestinal epithelium consists of different cell types such as absorptive epithelial cells 
(or enterocytes), mucin-secreting goblet cells, endocrine cells, and Paneth cells that secrete 
lysozyme and antimicrobial peptides [18]. The enterocytes secrete digestive enzymes and 
have hair-like projections on the apical membrane called microvilli that further increase the 
absorptive surface area up to 300–400 m2 [20]. Another cell type, M cells, are only 
associated with Peyer’s Patches, which are organized components of the gut-associated 
lymphoid tissue (GALT). The role of M cells in the intestinal epithelium is to transport 
antigens through a non-degradative pathway to dendritic cells in the Peyer’s Patches [21].
1.3 Challenges of Oral Delivery
The challenge of oral delivery is a result of the obstacles presented by the GI tract. These 
obstacles include exposure to a wide range of pH environments, enzymatic degradation, and 
poor permeability across the intestinal epithelium. The pH in the GI tract can vary from 1 in 
the stomach to 8 in parts of the intestine [22]. Exposure to these pH values can result in pH-
induced oxidation, deamidation, or hydrolysis of protein therapeutics, resulting in a loss of 
activity [23]. Enzymatic degradation is caused by proteases, nucleases, and lipases present in 
the GI tract for digestion of biological molecules prior to absorption [24]. If these obstacles 
are overcome, the therapeutic must then reach the epithelial barrier for absorption. The 
obstacles presented by the epithelium consist of extrinsic and intrinsic barriers [25].
The extrinsic barrier consists of the mucus layer covering the epithelial cells. The mucus 
layer is a complex hydrogel material composed of proteins, carbohydrates, lipids, salts, 
antibodies, bacteria, and cellular debris [26,27]. It consists of loosely and firmly adherent 
layers that vary in thickness along the GI tract and can fluctuate based on diet [28]. The 
mucus layer serves several roles. It aids in digestion by lubricating food particles to facilitate 
transport along the GI tract. It also protects epithelial surfaces by trapping pathogens and 
foreign particulates and rapidly clearing them [29]. Penetration of this mucus barrier is 
necessary in order to reach the absorptive epithelial cells.
The intrinsic barrier consists of the epithelial cell monolayer, which is the major transport 
barrier for material from the intestinal lumen to the lamina propria. Cells maintain this 
barrier by forming tight junctions, which are fusions between lateral membranes of adjacent 
cells [30,31]. Through specific combinations of different proteins, the permeability of the 
tight junctions can be modulated [32,33]. Intestinal cells also have metabolic systems and P-
glycoprotein (P-gp) drug efflux pumps that can cause low bioavailability for many small 
molecule therapeutics such as chemotherapeutic agents [34].
Pridgen et al. Page 3
Expert Opin Drug Deliv. Author manuscript; available in PMC 2016 April 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
For NPs, an additional obstacle is the immune system, which is intimately associated with 
the epithelium. Numerous types of immune cells patrol the lamina propria, including T cells, 
macrophages, and dendritic cells [21]. If NPs reach the bloodstream, they must also evade 
the mononuclear phagocytic system (MPS) while releasing their therapeutic cargo.
1.4 Intestinal Transport Pathways
There are several pathways across the epithelial barrier that could be used for oral delivery 
[19] (Figure 2). The transcellular pathway passes through the apical and basolateral cell 
membranes as well as the cytoplasm. This pathway is very restrictive to the passive flow of 
hydrophilic solutes because of the lipid bilayer membrane and is impermeable for large 
molecules. Mechanisms of transport for this pathway can be passive for hydrophobic 
molecules or active if a membrane pump is present for specific molecules such as ions. The 
paracellular pathway is the major passive permeation pathway and allows diffusion of small 
molecules in the space between epithelial cells. The tight junctions regulate the permeability 
of this pathway based on the size and charge of the molecules [31,35]. Transcytosis is an 
active transport pathway that relies on receptors specific for a molecule to guide the 
molecule through the cell without entering a degradation pathway. Because of their large 
hydrodynamic size, macromolecules, such as biologics, and NPs are restricted to this 
pathway for transport across the cellular barrier.
1.5 Polymeric Nanoparticles
Polymeric NPs have been extensively studied for oral delivery and have several advantages 
over other technologies [36,37]. NPs are stable in the GI environment and can protect 
encapsulated therapeutics from the pH environment, enzyme degradation, and drug efflux 
pumps [7,38]. For example, when exposed to proteases, insulin and calcitonin stability was 
improved through encapsulation in polymeric NPs [39,40]. Using polymers to form the NPs 
provides considerable design flexibility by enabling modulation of physicochemical 
properties (size, surface charge, hydrophobilicity) and drug release properties (controlled or 
triggered by external stimuli) [41]. Furthermore, the surface properties can be modulated by 
using different polymer end groups or conjugating polymers to the NP surface [42]. 
Targeting ligands such as antibodies, peptides, or small molecules can be conjugated to the 
surface as well to allow specific interactions with tissue components or cellular receptors 
[43]. NPs are also able to encapsulate a broad range of therapeutics such as nucleic acids 
such as DNA or small interfering RNA (siRNA), small molecule drugs, or biologics. The 
small size of NPs increases the specific surface area, allowing increased contact area with 
the epithelial surface and a greater potential for non-specific uptake or receptor-mediated 
endocytosis. Finally, polymeric NPs can be composed of biodegradable materials, many of 
which are approved for human use by the US Food and Drug Administration [3,44].
2. Strategies for Oral Delivery
2.1 Mucoadhesives
There are two different approaches for oral drug delivery that involve the mucus overlaying 
the intestinal epithelial cells: mucus-penetrating materials and mucoadhesive materials 
(Figure 3). Mucus-penetrating materials enable NPs to diffuse through the mucus layers and 
Pridgen et al. Page 4
Expert Opin Drug Deliv. Author manuscript; available in PMC 2016 April 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
interact directly with the epithelial cells. One method to overcome the mucus barrier is to 
modify the surface of the NPs with polyethylene glycol (PEG). Dense PEG coating of NP 
surfaces minimizes interactions between NPs and mucus, enabling penetration of mucus 
barriers [45].
Mucoadhesives are biomaterials designed to interact with the intestinal mucus layer to 
increase the residence time and contact with the epithelium, resulting in an increase in the 
concentration of released therapeutics at the site of absorption [46] (Figure 1). 
Mucoadhesion can be achieved through several mechanisms, including hydrogen bonding, 
electrostatic interactions, polymer entanglements with mucus, or a combination of these 
mechanisms [47–49]. Some examples of polymers used as mucoadhesives include chitosan 
[50], polyacrylic acid (PAA) [49], and poly(fumaric-co-sebacic) anhydride [51].
Several polymer properties can affect mucoadhesion strength [52]. Studies with chitosan 
particle revealed that higher polymer molecular weight increases mucoadhesion [53]. In 
another study, PAA hydrogels had long flexible poly(ethylene) (PEG) chains conjugated to 
the surface. Mucoadhesion was enhanced due to PEG chain penetration and entanglement in 
the mucus network [54]. Because mucins are negatively charged, chitosan amine groups on 
the surface of NPs adhere to mucus through electrostatic interactions [26]. Since the 
protonation of the amines varies with pH, the mucoadhesive properties due to electrostatic 
interactions of chitosan NPs vary along the GI tract and may be mucoadhesive only in 
certain regions of the intestine with acidic pH values [55,56]. Finally, thiol functional groups 
can enhance mucoadhesion [57]. Studies of chitosan NPs with thiol groups on the surface 
showed enhanced mucoadhesion due to covalent bonds formed between thiols and cysteine 
residues on mucus glycoproteins [58].
Besides increasing the concentration of therapeutics near the epithelium, many 
mucoadhesive materials increase intestinal absorption of therapeutics by acting as 
permeation enhancers, reversibly opening tight junctions to enhance paracellular transport 
[59]. Because the tight junctions are less than 20 nm in diameter when opened, most NP 
drug delivery systems are still unable to pass through this pathway [60]. In a study where 
chitosan was conjugated to quantum dots (QDs) and orally administered to mice, 
transmission electron microscopy of intestinal sections revealed chitosan-QD aggregates in 
the microvilli, but few particles in the paracellular spaces and none on the basolateral side of 
the intestines [61]. However, opening of the tight junctions does allow many therapeutics to 
cross using the paracellular pathway. In a study of NPs composed of chitosan and poly(γ-
glutamic acid) (PGA) encapsulating aspart-insulin and orally administered to rats, 
biodistribution results showed that the aspart-insulin was absorbed and entered systemic 
circulation while the NPs were retained in the intestine [62].
One disadvantage of this approach is that the permeation enhancer activity is non-specific, 
potentially allowing toxins and other pathogens present in the intestines to cross the 
intestinal barrier once the tight junctions are open [63]. In a study of the effect of insulin-
loaded chitosan NPs on the absorption of lipopolysaccharide (LPS), one of the most 
prevalent toxins in the GI tract, it was found that chitosan did not significantly increase the 
absorption of LPS but did enable insulin to reach circulation [64]. However, this may have 
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been due to anionic LPS forming micelles that were repulsed by the negative charge of the 
mucus layer. When mucolytic agents were added, LPS absorption was observed, suggesting 
that toxins that are not repulsed by mucus could enter through openings in the tight 
junctions. Therefore, the issue of toxicity associated with permeation enhancers warrants 
further study. One other limitation of the use of paracellular pathway for transport is that the 
surface area for absorption from the paracellular pathway is less than 0.1% of the total 
intestinal epithelium surface area, which could limit the capacity for absorption of 
therapeutics [65].
2.2 Targeting M cells
Targeting NPs to natural transcytosis pathways is another approach used for oral delivery 
because it offers a way to cross the intestinal barrier without affecting barrier permeability. 
The most extensively studied for oral delivery is the M cell transcytosis pathway, which is 
used to transport antigens across the epithelium for immune surveillance [21,66] (Figure 1). 
This pathway is attractive because M cells have reduced protease activity, a lack of mucus 
secretion, and a sparse glycocalyx [67].
There are many ways to engineer NPs to target M cells. Hydrophobicity is one parameter 
that influences uptake, with studies indicating that NPs formed using hydrophobic polymers 
(polystyrene, polymethylmethacrylate, and polyhydroxybutrate) had significantly more 
uptake by M cells than less hydrophobic lactide and glycolide polymer particles [68]. 
However, hydrophobicity could also enhance interactions with mucus, so further 
optimization may be needed [26]. Particle size studies have indicated that larger NPs are 
more selectively taken up by M cells [69,70]. Optimization of the surface charge has been 
more difficult, and it remains unclear exactly how surface charge affects non-specific uptake 
by M cells. In one study, neutral NPs ranging in size from 130 to 950 nm were identified as 
ideal for uptake by M cells [71]. Others have hypothesized that a positive charge would 
enhance interactions with the negatively-charged surface of M cells. However, the negative 
charge of mucus could also interact with the NPs, reducing the effectiveness of M cell 
targeting [72]. Using targeting ligands conjugated to the NP surface, such as bacterial 
adhesins [73], IgA antibodies [74], and toxins [75], also enhances M cell transport. In one 
study, IgA absorbed to polystyrene particles was taken up by M cells 20–30 times more than 
polystyrene particles coated with bovine serum albumin (BSA) [74].
One potential problem with this approach is that M cells are closely associated with immune 
cells in the lamina propria such as dendritic cells and macrophages that are part of the 
Peyer’s Patches [76]. A recent study demonstrated that the majority of fluorescently-labeled 
glucan and PLGA NPs administered orally to mice were endocytosed by dendritic cells in 
the Peyer’s Patches after M cell transcytosis, preventing the NPs from reaching the 
bloodstream [77]. Besides limiting the ability of the NPs to deliver the therapeutics to the 
bloodstream, uptake by dendritic cells increases the risk that the NPs or therapeutics could 
induce an immune response [78]. While this may limit the use of this approach for long-term 
oral administration, it opens the possibility that NPs targeting M cells could be used for oral 
mucosal vaccination applications [79].
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Absorption of NPs or therapeutics by M cells may also be limited because M cells only 
make up a small percentage (5–10%) of the non-absorptive epithelium in humans [80,81]. 
The number of Peyer’s Patches and surface properties of M cells also varies among species, 
which could make it difficult to use rodent data to predict performance in humans [82,83].
2.3 Targeting Enterocytes
Enterocytes are an attractive target for oral drug delivery because these cells form the 
majority of the absorptive surface area of the intestine. In the proximal jejunum of rats, the 
ratio of M cells to enterocytes was estimated to be 1:12 [84]. One of the challenges of 
targeting enterocytes is penetrating the mucus layer covering the cells so that the NPs can 
interact directly with the cell surface. As mentioned earlier, coating NPs with mucus-
penetrating materials such as a dense outer layer of PEG enables the NPs to diffuse through 
the mucus barrier and reach the epithelial cell surface [45].
Several NP physicochemical parameters have been used to enhance enterocyte particle 
uptake. Particle size studies have indicated that smaller NPs (<50–100 nm) are taken up by 
enterocytes [69,70]. Studies of PLGA NPs in vitro with Caco-2 cells (human 
adenocarcinoma cell line) and in vivo in rats revealed that uptake of 100 nm particles was 
more efficient than larger particles (500 nm, 1 μm, 10 μm) [85,86].
In addition to physicochemical properties, there are several different ligands that have been 
used to target NPs to enterocytes. One example is lectins, a class of proteins that specifically 
bind to carbohydrates and have been investigated for receptor-mediated oral delivery 
because of their resistance to acidic pH and proteases as well as having a large number of 
binding sites on the glycocalyx of epithelial cells [87,88]. Studies with tomato lectin-
conjugated NPs have shown that the targeted NPs have increased endocytosis through 
enhanced interactions with enterocytes [89,90]. Another lectin is wheat germ agglutinin 
(WGA), which binds to N-acetyl glucosamine and sialic acid found throughout the GI tract 
[91]. Studies with WGA demonstrated that it not only binds to the surface of enterocytes, 
but is taken up into the cells by receptor-mediated endocytosis through the epidermal growth 
factor receptor that is highly expressed on enterocytes [92]. One disadvantage of lectins is 
that they may also interact with components of the mucus layer, which causes them to act as 
bioadhesives and prevents NPs from reaching the epithelial surface [93,94]. In addition, 
lectins have not been shown to traffic through a transcytosis pathway. Therefore, NPs taken 
up either remain on the surface or, if endocytosed, may be trafficked through a degradation 
pathway to the lysosomes.
The folate receptor is another target of NPs for oral delivery that has demonstrated enhanced 
uptake of drugs encapsulated in folate-targeted NPs [95]. However, there is very limited 
evidence that folate receptors enable transcytosis across enterocytes. Lectins and folic acid 
ligands may be better suited for targeting of NPs directly to enterocytes for local delivery of 
therapeutics rather than systemic delivery after oral administration (Figure 1).
More recent NP targeting strategies have focused on receptor-mediated transcytosis 
pathways that are not associated with the GALT, which may help NPs evade immune cells 
after crossing epithelium (Figure 1). One example of this strategy is the vitamin B12 
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receptor. When vitamin B12 is ingested, it is bound by a protein called intrinsic factor (IF) in 
the small intestines. The vitamin B12-IF complex interacts with a receptor that traffics 
vitamin B12 across the intestinal epithelium [96]. As part of the pathway across the cell, the 
vitamin B12-IF complex enters the lysosomal compartment, which could potentially lead to 
inactivation of released therapeutics. Interestingly, conjugating vitamin B12 to NPs causes a 
switch in the transcytosis pathway used to cross the enterocytes. Studies have shown that 
vitamin B12-NP conjugates are able to avoid trafficking through lysosomes, while either 
vitamin B12 or non-targeted NPs pass through lysosomes in Caco-2 in vitro models [97]. 
Targeting of NPs to this pathway by conjugating vitamin B12 to the NP surface has been 
successful in delivering biologics to the bloodstream. Studies with insulin-loaded NPs 
targeted to the vitamin B12-IF receptor have demonstrated enhanced absorption of insulin 
and hypoglycemic effects in rat models after oral administration [98,99]. One potential 
drawback of this approach is that vitamin B12 absorption does not occur until the distal 
section of the ileum, requiring NPs to maintain stability while traveling through most of the 
small intestine before absorption.
Another receptor recently targeted by NPs for oral delivery is the neonatal Fc receptor 
(FcRn). FcRn is responsible for IgG transport across the intestinal epithelium [100,101], and 
is expressed throughout the intestine [102] (Figure 3). FcRn binds to the Fc region of IgG 
antibodies in a pH-dependent manner, with high affinity in acidic environments (pH <6.5) 
and low affinity at physiological pH (pH ~ 7.4) [103]. NPs can be targeted to FcRn by 
conjugating the Fc fragment of IgG to the surface of NPs. In acidic sections of the intestine 
such as the duodenum and jejunum [104], targeted NPs can bind to FcRn on the surface of 
enterocytes. Alternatively, in later sections of the intestine, targeted NPs can still be taken up 
through fluid-phase pinocytosis by enterocytes and be bound by FcRn once inside acidic 
endosomes [105]. Once bound to FcRn, targeted NPs can be trafficked across enterocytes. 
On the basolateral side of the cell, where the pH is neutral, targeted NP are released from 
FcRn and are free to diffuse into the lamina propria. In a recent study, Fc-targeted NPs 
administered orally to mice were absorbed 11.5 times more efficiently than non-targeted 
NPs, and the NPs were able to enter systemic circulation [106]. The Fc-targeted NPs were 
detected in the liver, spleen, lungs, and kidneys after absorption, which are all tissues that 
express the FcRn. Therefore, using IgG Fc to target the FcRn not only enables NPs to cross 
the intestines, but it also targets the NPs to several of the organs expressing FcRn. The study 
also demonstrated that administering Fc-targeted NPs containing insulin resulted in a 
hypoglycemic response for 15 hr with a clinically-relevant dose of only 1.1 U/kg [107], 
lower than other oral insulin delivery systems that require 10–100 U/kg to generate a 
glucose response [19]. One drawback of this approach is the potential for Fc fragments on 
the NP surface to interact with other Fc receptors in the body once absorbed, which could 
affect NP biodistribution and possibly cause an immune reaction.
3. Applications
3.1 Cancer Therapies
There are some chemotherapeutic agents that can be administered orally. However, many 
suffer from low bioavailability due to physicochemical properties or because they are 
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substrates for P-gp proteins that pump drugs taken up by enterocytes back into the intestinal 
lumen. Encapsulating chemotherapeutic agents in NPs can enable oral administration of 
agents currently limited to intravenous administration. Taxanes are one example of a 
chemotherapeutic agents limited by low bioavailabiity due to P-gp pumps [108]. In a recent 
study, encapsulating docetaxel in NPs resulted in increased absorption after oral 
administration relative to oral Taxotere in mini pigs [109]. Furthermore, the study showed 
that docetaxel NPs were trafficked through the lymphatic system, avoiding first-pass liver 
metabolism effects such as degradation by cytochrome P450 3A4 (CYP3A4). This resulted 
in higher drug levels in the blood than intravenously administered Taxotere, reduced tumor 
growth, and increased survival in a mouse lung cancer metastatic model. Rapamycin was 
encapsulated in NPs composed of N-isopropylacrylamide, methylmethacrylate, and acrylic 
acid and administered orally to mice [110]. The NP formulation resulted in higher levels of 
drug in the blood and in xenograft pancreatic cancer tumors compared with free rapamycin 
administered orally. In addition, there was no evidence of toxicity in the intestines or other 
visceral organs from the oral rapamycin NPs after 4 weeks.
3.2 Proteins and Peptides
One of the biggest goals for oral delivery is insulin because of the chronic nature of the 
therapy and the need for multiple daily injections. In addition to the patient convenience, 
oral delivery is particularly beneficial for insulin because it more closely reproduces 
insulin’s physiological pharmacokinetic profile. Subcutaneous insulin injection targets 
tissues such as muscle and kidney because it enters systemic circulation first before reaching 
the liver [111]. The oral route replicates the pharmacodynamics of endogenous insulin 
release by entering the liver after intestinal absorption, similar to insulin secreted from the 
pancreas [50]. The liver metabolizes 50–75% of insulin secreted from the pancreas, but only 
25% of subcutaneous insulin [112]. The liver is more sensitive to insulin and acts faster in 
response to insulin to lower blood glucose levels; therefore, less insulin is required to control 
blood glucose levels, even in diabetic patients [111].
Oral insulin delivery has been achieved using many approaches such as mucoadhesives, M 
cell targeting, and enterocyte targeting. However, many of these technologies have been 
limited by inefficiency, requiring high doses of insulin to generate a hypoglycemic response 
in rodent models. Previous studies have suggested that long-term oral administration of high 
doses of insulin could induce mitogenic changes in GI epithelial cells because insulin is a 
growth factor [113]. However, recent technologies are becoming more efficient and are using 
more clinically relevant insulin doses to achieve hypoglycemic response in mice [106]. 
Studies with insulin encapsulated in NPs have also demonstrated that controlled release of 
insulin from NPs results in a more prolonged hypoglycemic effect with less of a decrease in 
blood glucose than subcutaneous insulin administration [62].
There are several other examples of peptides and proteins being delivered orally using NPs. 
Interferon-β (INF-β) is used for the treatment of multiple sclerosis, but is limited to daily 
injections [114]. By encapsulating INF-β in NPs, INF-β was able to be administered orally to 
rabbits and achieved higher plasma concentration over 24 hrs compared with subcutaneous 
injection [115]. Salmon calcitonin is a peptide that causes a decrease in blood calcium levels 
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and is used for the treatment of bone diseases such as osteoporosis [116]. When 
encapsulated in Eudragit®-PLGA NPs, it was able to be administered orally to rats and 
achieve a greater decline in blood calcium levels for 24 hrs compared with subcutaneous 
injections of free salmon calcitonin [117]. Finally, cyclosporine is a potent 
immunosuppressive agent used for the prevention of graft rejection [118]. When 
encapsulated in PLGA NPs and administered orally to rats, the cyclosporine NPs resulted in 
a sustained blood concentration of cyclosporine over 5 days compared with only 3 days for 
the commercial formulation and had markedly less nephrotoxicity [119].
3.3 Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a target for oral delivery because the affected tissue is 
the intestines. As opposed to most oral delivery applications that require the therapeutic to 
reach the bloodstream, the goal for IBD treatment is local delivery of therapeutics to 
immune cells in the intestines. Oral delivery strategies for IBD have attempted to take 
advantage of the pathophysiological processes associate with the disease to deliver therapies 
only at inflamed intestinal regions. These processes include increased mucus production and 
enhanced permeability of the intestinal barrier at inflammation sites [120]. By delivering 
anti-inflammatory therapies locally instead of systemically, the therapies can be 
concentrated at inflammation sites for greater efficacy while minimizing systemic adverse 
side effects [121,122].
Physicochemical NP parameters can be used to target inflamed intestinal tissue. In a rat IBD 
model, smaller NP sizes were more effective at depositing in inflamed tissue [123]. Within 
the inflamed tissue, greater deposition was observed in regions of thicker mucus and 
ulcerations. NPs have been effective at delivering many different therapeutics, including 
rolipram [124], 5-aminosalicylic acid [125], FK506 (tacrolimus) [120], and dexamathesone 
[121], with each demonstrating efficacy in reducing inflammation in rodent IBD models.
Another approach to target IBD is to attach ligands to the surface of NPs. In one study, the 
Fab portion of the F4/80 antibody was conjugated to the surface of PLA-PEG NPs 
containing TNF-α siRNA [126]. When administered to mice with colitis, the targeted NPs 
demonstrated reduced inflammation and body weight loss compared to control groups. 
Lectins such as WGA and peanut agglutinin (PNA) have also been used to target IBD. When 
conjugated to PLGA NPs, both WGA and PNA caused increased adherence of NPs to 
inflamed regions of the intestine and improved clinical activity scores in murine colitis 
models [127].
Polymer engineering has also been used to target inflammation in IBD models. Thioketal 
polymers were synthesized that selectively degraded in the presence of reactive oxygen 
species (ROS) [128]. Because inflammatory sites have elevated levels of ROS, NPs 
composed of thioketal polymers would degrade at inflammation sites after oral 
administration and release the therapeutic cargo (Figure 5). TNF-α siRNA was encapsulated 
in thioketal NPs and administered to mice with induced colitis, and the results showed that 
the thioketal NPs reduced inflammation and body weight loss over 7 days.
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3.4 Vaccines
NPs are also being developed for oral vaccination applications. Chitosan NPs containing 
DNA have been used to generate immune protection against several allergens. For example, 
mice administered orally with chitosan NPs containing a peanut allergen gene demonstrated 
reduced allergen-induced anaphylaxis compared with non-immunized mice [129]. Chitosan 
NPs containing a gene for allergens derived from house dust mites were also used for oral 
vaccination of mice [130]. Results showed that oral administration of the NPs led to 
expression of the gene in epithelial cells of the stomach and small intestines, preventing 
sensitization of a Th2 cell-regulated IgE response [131].
NPs have also been developed for vaccination against bacterial and viral infections. PLGA 
particles containing Staphylococcal enterotoxin B given orally to mice were taken up by M 
cells in the Peyer’s Patches and resulted in the production of circulating toxin-specific 
antibodies and secretory IgA-specific antibodies in saliva, gut wash fluids, and bronchial-
alveolar wash fluids [68,132]. In contrast, soluble enterotoxoid administered orally was 
unable to generate an immune response. In another study, NPs encapsulated in pH-
dependent microparticles were developed that could be targeted specifically to either the 
small or large intestine [133]. The system was used to vaccinate the colon against a viral 
infection challenge as an effective alternative to intracolorectal administration.
4. Conclusions
Many therapeutics are currently limited to parenteral administration. Alternate routes of 
administration, particularly oral, are considered favorable because they are more convenient 
and have improved patient compliance than injection-based administration. However, oral 
delivery is very challenging because of the barriers presented by the GI tract. Polymeric NPs 
can be used to overcome the pH and enzyme barriers, but the intestinal permeability barrier 
remains a significant hurdle.
There have been many approaches used to overcome the intestinal epithelial barrier to 
enable efficient oral delivery of biologics and nanomedicines. Mucoadhesives use the mucus 
layer of the intestines to prolong residence time in the intestines and increase the 
concentration of therapeutics near the surface of the epithelial cells. In addition, many 
mucoadhesives are permeation enhancers that open tight junctions between epithelial cells to 
enable drugs or biologics to cross the barrier. Other approaches have focused on targeting 
natural transcytosis pathways, such as M cells, the vitamin B12 pathway, and the FcRn 
pathway. Recent studies have demonstrated that targeting transcytosis pathways can 
efficiently deliver therapeutics and nanomedicines orally, but further studies are required 
before these technologies can be translated to the clinic.
Oral NP drug delivery systems are being developed for many different applications. These 
include oral administration of chemotherapeutics for cancer treatments, local delivery to the 
intestine for the treatment of IBD, and oral mucosal vaccination. Many proteins are being 
encapsulated in NPs for oral administration, in particular insulin for the treatment of 
diabetes. Successful development of NPs for oral administration could change the treatment 
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paradigm for many of these diseases and have a significant impact on patient outcomes in 
the future.
5. Expert Opinion
Biologics and emerging nanomedicines have the potential to significantly alter the treatment 
of many diseases. However, both types of therapeutics are currently limited to parenteral 
administration because of intestinal barriers that limit absorption. Polymeric NPs are 
currently being investigated to enable efficient oral administration of these therapeutics. 
While polymeric NPs are able to overcome many of the challenges presented by the GI tract, 
the major hurdle of improving transport across the intestines remains.
There have been many different approaches developed to overcome the transport barrier 
presented by the GI tract. Mucoadhesives adhere to the mucus layer to increase therapeutic 
concentrations near epithelial cells and also cause reversible opening of tight junctions. 
While this approach utilizes the majority of intestinal surface area for adherence, there are 
safety issues associated with disrupting tight junction integrity. In addition, transport through 
tight junctions is limited by size to small molecules and biologics, and is not a valid 
approach for nanomedicines.
Another approach is to target NPs to the M cells in the Peyer’s Patches, which are part of the 
GALT. This strategy aims to take advantage of the transcytosis pathway used by M cells to 
transport antigens across the epithelium. Targeting transcytosis pathways could not only 
enable small molecules and biologics to cross the barrier, but it could also allow NPs to 
cross and reach systemic circulation. This would be a significant advance towards clinical 
development of nanomedicines for oral administration. However, the Peyer’s Patches only 
compose a small fraction of the surface area of the intestines and could limit absorption 
capacity. In addition, there is the potential for NPs that are transported across the epithelium 
to be taken up by these immune cells associated with M cells before entering systemic 
circulation. Alternatively, the association with immune cells makes this approach appealing 
for oral mucosal vaccination.
Recent approaches have tried to combine the advantages of these previous strategies by 
attempting to target transcytosis pathways present in intestinal epithelial cells. These cells 
are present throughout the majority of the intestines to maximize absorption capacity, but are 
not highly associated with the GALT so that interactions with immune cells after 
transcytosis may be reduced. Because this approach takes advantage of natural transcytosis 
pathways, it does not have to disrupt the integrity of the epithelial barrier. Examples include 
the vitamin B12 and the FcRn transcytosis pathways.
Despite all of the efforts focused on developing polymeric NPs for oral delivery, these 
technologies have historically been limited by low bioavailabilities. In the case of insulin 
delivery, this has resulted in the use of extremely high doses of insulin that would be 
impractical in clinical use. However, recent studies targeting transcytosis pathways such as 
the FcRn have achieved hypoglycemic effects in mouse models while significantly lowering 
insulin doses to levels approaching those used in the clinic for diabetic patients. In addition, 
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this approach enabled NPs, not just insulin, to reach the bloodstream and target organs 
expressing the FcRn.
While these are positive developments for the oral delivery of biologics and NP-based 
therapies, there are still many challenges that remain for translation of these technologies to 
the clinic. Because none of the NP oral delivery technologies have been tested in humans, it 
will be important to study how predictive animal models are for performance in humans in 
order to better evaluate different technologies. For example, the number of M cells can vary 
between species [134]. These differences could significantly affect absorption rates in 
different species [106,135]. In addition, understanding how patient-to-patient variability, 
diet, fasting states, and disease states affect the performance of these technologies in humans 
will be important to determine the robustness of these technologies. It will also be necessary 
to evaluate the consequences of long-term oral administration of therapeutics since some 
agents can act as growth factors and cause changes in the epithelium, while others may 
cause intestinal toxicity. Finally, since many of these oral delivery strategies require 
attaching targeting ligands to the NP surface, it will be important to study how the presence 
of these ligands on the NPs affects pharmacological parameters such as the biodistribution 
and blood clearance after absorption.
Further improvements in polymeric NP oral delivery technologies will come from increased 
understanding of the physiology of the intestines, including transcytosis pathways. In 
addition, a better understanding of disease pathophysiology could provide insights that result 
in new approaches, such as the example of developing ROS-responsive polymers to target 
therapies directly to inflammation sites in IBD. NPs are currently entering clinical trials for 
the treatment of many diseases, and are demonstrating that nanomedicines are a valid 
therapeutic modality that can feasibly be implemented in the clinic. In the future, it is 
expected that more polymeric NP technologies will be developed for oral delivery to allow 
biologics and nanomedicines to realize their full potential in the treatment of many chronic 
diseases.
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Article Highlights
• This article covers polymeric nanoparticle technologies being developed for the 
oral delivery of small molecule drugs, biologics, and nanomedicines.
• Background will be provided on the challenges associated with oral delivery for 
different classes of therapeutics.
• Different strategies used to overcome the barriers of the gastrointestinal tract by 
nanoparticles will be reviewed, including the use of mucoadhesive biomaterials 
and the targeting of nanoparticles to transcytosis pathways present in M cells 
and enterocytes.
• Applications currently being evaluated for oral delivery using nanoparticles will 
be discussed such as oral chemotherapy, oral insulin administration, oral 
treatments for inflammatory bowel disease, and oral mucosal vaccinations.
• Advantages and disadvantages of different approaches to oral delivery using 
nanoparticles will be considered.
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Figure 1. 
Schematic illustration of the intestinal epithelium and NP strategies for oral delivery. The 
epithelium includes absorptive epithelial cells, goblet cells that secrete mucus, and Paneth 
cells that secrete lysozyme and antimicrobial peptides. A Peyer’s Patch is shown with an M 
cell (M) and underlying immune cells such as dendritic cells (DCs) and lymphocytes. The 
barriers to oral delivery include acidic pH and enzymes present in the intestinal lumen, a 
mucus layer above the epithelial cells, the epithelial monolayer with restricted permeability 
due to tight junctions, and immune cells associated with the M cells. Strategies for oral 
delivery include: (A) NPs formed from mucoadhesive materials that adhere to the mucus 
layer and release drugs near the epithelial cells as well as reversibly open tight junctions for 
paracellular transport of therapeutics; (B) Receptor-mediated transcytosis of targeted NPs 
that enable NPs to cross the epithelium and reach the lamina propria; (C) Receptor-mediated 
uptake of targeted NPs for local drug delivery to epithelial cells instead of systemic delivery; 
(D) M cell transcytosis pathway that allows NPs to cross the epithelium, but with the 
potential for underlying DCs associated with Peyer’s Patches to endocytose NPs after 
crossing.
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Figure 2. 
Pathways for intestinal transepithelial transport include paracellular, transcellular, and 
transcytosis pathways. The paracellular pathway allows diffusion of molecules in the space 
between epithelial cells and is regulated by tight junctions formed between the cells. The 
transcellular pathway passes through the apical and basolateral cell membranes as well as 
the cytoplasm. It is restricted to hydrophobic molecules or molecules that have membrane 
pumps on the cell surface. The transcytosis pathway is an active transport pathway that relies 
on receptors specific for a molecule to guide molecules through the cell without entering a 
degradation pathway. Transcytosis pathways are found in both epithelial and M cells.
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Figure 3. 
Schematic illustration of the two oral drug delivery approaches that involve mucus: mucus-
penetrating particles (MPP) and conventional mucoadhesive particles (CP). MPP are able to 
diffuse through the mucus layers and reach the epithelium for direct interactions with the 
surface of epithelial cells. In contrast, CP adhere to the mucus and release therapeutics that 
can then diffuse to the epithelial surface. CP are cleared along with the mucus layers while 
MPP clearance depends on the interactions with the epithelial cells. Reproduced with 
permission from ref [26] and [47].
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Figure 4. 
(A) Schematic of NP transport across the intestinal epithelium using the FcRn transcytosis 
pathway. (B) Immunohistochemistry on mouse duodenum tissue sections showing 
expression of the FcRn in the intestinal epithelium. Mouse FcRn appears brown in the 
images. The negative control for the staining was polyclonal IgG. (C) Biodistribution of 14C-
labeled NPs after oral administration to mice demonstrating that NP-Fc were able to enter 
systemic circulation and reach the liver, lungs, and spleen significantly more than non-
targeted NPs. (D) Blood glucose response of fasted mice to orally administered NPs. NP-Fc 
was able to generate a significantly greater hypoglycemic response than non-targeted NPs. 
Adapted with permission from ref. [106].
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Figure 5. 
Targeting intestinal inflammation for IBD therapy using polymer engineering. (A) Thioketal 
linkages that are ROS-sensitive were incorporated into a polymer, causing the polymer to 
degrade in the presence of ROS. (B) Since inflammatory sites have elevated ROS levels, the 
NPs preferentially degrade and cause targeted release of the NP payload at sites of IBD. 
Reproduced with permission from [128].
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